Drugs / Placental Matrix-Derived Mesenchymal Stem Cells
Placental Matrix-Derived Mesenchymal Stem Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02395029 | Aug 2013 → Dec 2014 | Peyronie disease | Melissa Marchand | Completed | No outcome recorded |
| Phase 1 | NCT02398370 | Jul 2013 → Dec 2014 | erectile dysfunction | Melissa Marchand | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Placental Matrix-Derived Mesenchymal Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02398370 ↗ |
| Known as | PM-MSCs | “OBJECTIVE: To determine the feasibility and effects of using placental matrix-derived mesenchymal stem cells (PM-MSCs) in the treatment of patients with ED.” PMID 26745574 ↗ Jan 20161“using placental matrix-derived mesenchymal stem cells (PM-MSCs) in the management of PD” PMID 26414724 ↗ Oct 2015 |
| Known as | PMD-MSCs | “Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs).” NCT02398370 ↗1“Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)” NCT02395029 ↗ |
| Action | Restore | “Injecting PMD-MSCs into the penile corpora to replace the dysfunctional or dead cells” NCT02398370 ↗ |
| Modality | Cell therapy | “Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)” NCT02395029 ↗ |
| Route | Other | “intracavernosal injections of PMD-MSCs” NCT02398370 ↗ |